Anticoagulant therapy for percutaneous coronary intervention.
Rao
Sunil V
SV
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA.
Ohman
E Magnus
EM
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D000925:Anticoagulants / Q000494:pharmacology* / Q000627:therapeutic use; D000991:Antithrombins / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003328:Coronary Thrombosis / Q000188:drug therapy / Q000209:etiology*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D017984:Enoxaparin / Q000494:pharmacology / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000077425:Fondaparinux; D006629:Hirudins / Q000494:pharmacology; D006801:Humans; D017202:Myocardial Ischemia; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use; D015539:Platelet Activation / Q000187:drug effects; D011134:Polysaccharides / Q000494:pharmacology / Q000627:therapeutic use; D011183:Postoperative Complications; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013917:Thrombin / Q000235:genetics / Q000276:immunology / Q000378:metabolism
D000925:Anticoagulants; D000991:Antithrombins; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006629:Hirudins; D010446:Peptide Fragments; D011134:Polysaccharides; D011994:Recombinant Proteins; D013917:Thrombin; D000077425:Fondaparinux; C074619:bivalirudin